Furthermore, when investigated in a 4T1 TNBC orthotopic tumor model, PPGPL-CD155si/P exhibited excellent targeting of TNBC cells, additionally inducing a CD8+ TIL-dominant anti-tumor immune response to effectively hamper TNBC metastasis and progression with the least toxicity. Here, CD8A is linked to neoplasm.